Merck LLY-283

LLY-283

≥98% (HPLC)

(R)-5′-phenyl-7-deazaadenosine; 6-amino-9-[(R)-5′-phenyl(ribofuranosyl)]-7-deazapurine, (2R,3R,4S,5R)-2-(4-Amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((R)-hydroxy(phenyl)methyl)tetrahydrofuran-3,4-diol, LLY283, LLY 283

assay

≥98% (HPLC)

form

powder

색상

white to beige

저장 온도

2-8°C

SMILES string

O[C@@H]1[C@@H]([C@H](O)C2=CC=CC=C2)O[C@@H](N3C(N=CN=C4N)=C4C=C3)[C@@H]1O

LLY-283 is a potent and selective SAM-competitive PRMT5 inhibitor (IC50 = 20 nM against PRMT5-catalyzed methylation of an H4R3-derived peptide substrate) with greater than 100-fold selectivity over other histone methyltransferases and non-epigenetic targets. LLY-283 inhibits Smith (Sm) antigen SmBB′ methylation in MCF7 cells (IC50 = 25 nM; 3 days) and affects MDM4 splicing in A375 cells (IC50 = 40 nM; 3 days). The diastereomer LLY-284 is less potent in the biochemical assay and is an ideal control compound for cellular studies. For characterization details of LLY-283, please visit the LLY-283 probe summary on the Structural Genomics Consortium (SGC) website.

LLY-284 is the negative control for the active probe, LLY-283. LLY-284 is available from Sigma. To learn more about and purchase LLY-284, click here.

To learn about other SGC chemical probes for epigenetic targets, visit sigma.com/sgc